Dong-Wan Kim

Nov 8, 2024 | tandfonline.com | Byoung Chul Cho |Lyudmila A Bazhenova |Dong-Wan Kim |Sanjay Goel

AbstractAim: We report clinical activity and safety of sitravatinib in patients with advanced cancer from basket cohorts with specific molecular alterations, in a Phase Ib study. Materials & methods: Patients with advanced solid tumors harboring amplification, mutation, or rearrangement of MET, AXL, RET, NTRK, DDR2, KDR, PDGFRA, KIT or CBL received sitravatinib once daily. Primary end point was confirmed objective response rate (ORR).

Feb 13, 2024 | nature.com | Benjamin Besse |Sylvia Hartl |Patrick M. Forde |Melissa Johnson |Dong-Wan Kim |Boaz E. Aronson | +7 more

AbstractFor patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance to immune checkpoint blockade is common.